Jun2022
Ariana Pharma, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.
Paris and Cambridge, MA, June 15th 2022. Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have […]
Mar2022
Anavex Life Sciences and Ariana Pharma present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference
Pushing the promise of AI designed Precision Medicine Parkinson’s Disease Dementia (PDD) therapy closer to the finish line, Ariana, the AI Drug Development Company and ANAVEX Life Sciences announced positive ANAVEX®2-73 Phase II results.
Feb2022
Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment
May2021
Ariana appoints pharmaceutical industry drug development veteran
Prior to joining Ariana, Hichem was Director of Development Operations at Sanofi. Hichem’s significant achievements encompass multiple therapeutic areas
May2021
Ariana announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi
The ATRACTion project will generate clinical, multi-omic (single cell RNA expression, gut microbiota) and additional immunological data by investigating several auto-immune diseases.
May2021
Ariana Announces Appointment of Accomplished Business and Strategy Executive, Kia Motesharei to its Board of Directors.
Dr. Motesharei brings over 20 years of experience in management, strategy, business development, alliance management, product development and marketing across the biotechnology and pharmaceutical industry.
Apr2020
Towards a first precision medicine treatment of Alzheimer’s disease using Ariana’s Explainable AI.
Paris and Boston, April 17th 2020. Ariana® Pharma, a leading digital health company announced today the publication of the first reported genome-wide search for biomarkers associated with drug response in Alzheimer’s disease in the Alzheimer’s & Dementia: Translational Research & Clinical Interventions journal. Using Ariana’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, […]
Nov2019
Comorbidities play an important role in hospitalized influenza mortality risk, Real World Evidence (RWE) study performed by Ariana and Sanofi Pasteur shows
Big Data analysis of over 125 Million patient hospitalization records using Ariana’s data analytics and AI platform identifies significant factors increasing Case Fatality Rates Paris and Boston, November 7th 2019. Ariana Pharma, a leading digital health Company announced the publication of an influenza Real World analysis in collaboration with Sanofi-Pasteur. Influenza-related mortality for hospitalized patients […]
Sep2019
Towards a first precision medicine Immunotherapy for the treatment of Type 1 Diabetes using Ariana’s Artificial Intelligence
Ariana’s KEM® Artificial Intelligence technology identified immunological changes, which are early indicators of clinical effects, for selected groups of patients in a first-in-human Phase 1b study. The potential for a selection biomarker in patients receiving this therapy transforms design options for Imcyse’s future clinical trials in T1D and additional indications. On August 27th 2019, Imcyse, […]
Jul2019
Alzheimer’s Disease/Dementia Early Detection and Precision Medicine Using KEM® Artificial Intelligence (AI): latest research results presented by ARIANA at the AAIC 2019.
Gut Microbiota biomarkers associated with improved drug response, as well as genomic biomarkers for early detection of patients at risk were identified using Ariana’s KEM® Explainable AI (XAI) in 3 separate oral presentations. response, as well as genomic biomarkers for early detection of patients at risk were identified using Ariana’s KEM® Explainable AI (XAI) in […]